Abbott

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Abbott 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. 

CEO
Robert B. Ford
CEORobert B. Ford
Employees
115,000
Employees115,000
Headquarters
Abbott Park, Illinois
HeadquartersAbbott Park, Illinois
Founded
1888
Founded1888
Employees
115,000
Employees115,000

ABT Key Statistics

Market cap
193.06B
Market cap193.06B
Price-Earnings ratio
36.88
Price-Earnings ratio36.88
Dividend yield
2.17%
Dividend yield2.17%
Average volume
7.58M
Average volume7.58M
High today
$113.45
High today$113.45
Low today
$111.29
Low today$111.29
Open price
$113.45
Open price$113.45
Volume
8.35M
Volume8.35M
52 Week high
$137.49
52 Week high$137.49
52 Week low
$81.97
52 Week low$81.97

Stock Snapshot

Abbott(ABT) stock is priced at $111.76, giving the company a market capitalization of 193.06B. It carries a P/E multiple of 36.88 and pays a dividend yield of 2.17%.

As of 2026-08-27, Abbott(ABT) stock has fluctuated between $111.29 and $113.45. The current price stands at $111.76, placing the stock +0.4% above today's low and -1.5% off the high.

Abbott(ABT) shares are trading with a volume of 8.35M, against a daily average of 7.58M.

In the last year, Abbott(ABT) shares hit a 52-week high of $137.49 and a 52-week low of $81.97.

In the last year, Abbott(ABT) shares hit a 52-week high of $137.49 and a 52-week low of $81.97.

ABT News

24/7 Wall St. 4h
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Investing The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up? Abbott just scored a regulatory first in diabetes care that no r...

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
TipRanks 11h
Abbott’s Amulet 360 device granted CE Mark

Abbott (ABT) has received CE Mark for the Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce risk of stroke in patients with...

Simply Wall St 13h
Abbott Stock And Two Defensive Dividend Names For Uncertain Markets

Sticky July PCE inflation and a divided Federal Reserve keep markets on edge, while softer retail sales hint that consumers may be slowing down. That mix can pu...

Abbott Stock And Two Defensive Dividend Names For Uncertain Markets

Analyst ratings

81%

of 27 ratings
Buy
81.5%
Hold
18.5%
Sell
0%

More ABT News

Benzinga 1d
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring Syste...

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Simply Wall St 1d
Why Is Abbott Laboratories Launching A First Of Its Kind Diabetes Wearable?

Abbott Laboratories (NYSE:ABT) received FDA authorization for its Libre Duo 10 Day system, described as the world's first dual glucose ketone sensing biowearabl...

Why Is Abbott Laboratories Launching A First Of Its Kind Diabetes Wearable?
TipRanks 2d
Abbott receives FDA authorization for Libre Duo 10 Day system

Abbott (ABT) announced U.S. Food and Drug Administration authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology....

Nasdaq 3d
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

Key Points His purchases increased his exposure to pharmaceuticals, medical devices, diagnostics, and diabetes care. AbbVie is relying on drugs like Skyrizi a...

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.
Nasdaq 4d
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

Key Points Abbott Laboratories has faced challenges, but it should successfully overcome them. Johnson & Johnson is performing well, and there could be more t...

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?
TipRanks 6d
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Abbott Laboratories, boosting the price target to $135.00. Unlock powerful investing tools with Ti...

People also own

Based on the portfolios of people who own ABT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.